Skip to main content

Peer Review reports

From: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Original Submission
2 Jan 2024 Submitted Original manuscript
30 Jan 2024 Author responded Author comments - Carles Domènech
4 Feb 2024 Author responded Author comments - Carles Domènech
Resubmission - Version 2
30 Jan 2024 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
15 Mar 2024 Reviewed Reviewer Report
1 May 2024 Reviewed Reviewer Report
10 Jun 2024 Author responded Author comments - Carles Domènech
Resubmission - Version 5
10 Jun 2024 Submitted Manuscript version 5
Publishing
10 Jun 2024 Editorially accepted
22 Jul 2024 Article published 10.1186/s12885-024-12501-5

You can find further information about peer review here.

Back to article page